Answers are grounded in this paper and cite their sources.
The main purpose of performing interim analyses in a clinical trial is to stop the trial once a convincing treatment difference can be demonstrated. The major problem with repeated significance tests during inclusion and/or follow-up in a clinical trial is that the more often one analyses accumulating data, the greater the probability of obtaining a statistically significant result even when there is in reality no treatment difference. To allow for repeated testing, one must therefore choose a more stringent nominal significance level as a criterion for stopping the trial. This paper presents two simple strategies for undertaking interim analyses.
No takes yet. Share an insight, caveat, or question.
Eva Skovlund (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: